Kyntra Bio Inc (NASDAQ:KYNB – Free Report) – Analysts at HC Wainwright upped their Q2 2026 earnings estimates for shares of Kyntra Bio in a research note issued on Tuesday, May 12th. HC Wainwright analyst M. Keller now forecasts that the company will post earnings of ($3.62) per share for the quarter, up from their previous forecast of ($3.87). HC Wainwright currently has a “Strong-Buy” rating on the stock. The consensus estimate for Kyntra Bio’s current full-year earnings is ($13.54) per share. HC Wainwright also issued estimates for Kyntra Bio’s Q3 2026 earnings at ($3.87) EPS, Q4 2026 earnings at ($4.15) EPS, FY2026 earnings at ($15.37) EPS, FY2027 earnings at ($7.57) EPS and FY2028 earnings at ($7.76) EPS.
KYNB has been the topic of a number of other research reports. Weiss Ratings started coverage on shares of Kyntra Bio in a research note on Wednesday, January 14th. They set a “sell (d+)” rating on the stock. Wall Street Zen upgraded shares of Kyntra Bio from a “sell” rating to a “hold” rating in a research note on Saturday, April 18th. Finally, Zacks Research lowered shares of Kyntra Bio from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold”.
Kyntra Bio Stock Performance
NASDAQ KYNB opened at $7.00 on Thursday. The company has a market cap of $28.35 million, a price-to-earnings ratio of 0.17 and a beta of 1.03. The stock’s 50 day moving average price is $7.04. Kyntra Bio has a 52 week low of $4.85 and a 52 week high of $12.60.
Kyntra Bio Company Profile
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Featured Articles
- Five stocks we like better than Kyntra Bio
- Oklo Stock Could Be Ready for Another Massive Run
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
Receive News & Ratings for Kyntra Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyntra Bio and related companies with MarketBeat.com's FREE daily email newsletter.
